Assertio Holdings Inc (ASRT) USD0.0001

Sell:$0.66Buy:$0.67$0.00 (0.51%)

Prices delayed by at least 15 minutes
Sell:$0.66
Buy:$0.67
Change:$0.00 (0.51%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.66
Buy:$0.67
Change:$0.00 (0.51%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Key people

Brendan P. O'Grady
Chief Executive Officer, Director
Ajay Patel
Chief Financial Officer, Executive Vice President
Sam Schlessinger
Executive Vice President, General Counsel
Mary E Pietryga
Executive Vice President, Chief Commercial Officer
Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Heather L. Mason
Independent Chairman of the Board
Sravan K. Emany
Independent Director
Sigurd C. Kirk
Independent Director
William T. Mckee
Independent Director
Mark L Reisenauer
Independent Director
Click to see more

Key facts

  • EPIC
    ASRT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US04546C2052
  • Market cap
    $62.54m
  • Employees
    58
  • Shares in issue
    95.78m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.